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A ‘specificity’ pocket inferred from the crystal structures of the
complexes of aldose reductase with the pharmaceutically
important inhibitors tolrestat and sorbinil
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L Urzhumtseva1†, J-F Biellmann3, AD Podjarny1 and D Moras1*
Background: Aldose reductase (AR) is an NADPH-dependent enzyme
implicated in long-term diabetic complications. Buried at the bottom of a deep
hydrophobic cleft, the NADPH coenzyme is surrounded by the conserved
hydrophilic residues of the AR active site. The existence of an anionic binding
site near the NADP+ has been determined from the structures of the complexes
of AR with citrate, cacodylate and glucose-6-phosphate. The inhibitor
zopolrestat binds to this anionic site, and in the hydrophobic cleft, after a
change of conformation which opens a ‘specificity’ pocket.
Results: The crystal structures of the porcine AR holoenzyme and its
complexes with the inhibitors tolrestat and sorbinil have been solved; these
structures are important as tolrestat and sorbinil are, pharmaceutically, the most
well-studied AR inhibitors. The active site of the holoenzyme was analyzed, and
binding of the inhibitors was found to involve two contact zones in the active
site: first, a recognition region for hydrogen-bond acceptors near the coenzyme,
with three centers, including the anionic site; and second, a hydrophobic
contact zone in the active-site cleft, which in the case of tolrestat includes the
specificity pocket. The conformational change leading to the opening of the
specificity pocket upon tolrestat binding is different to the one seen upon
zopolrestat binding; this pocket binds inhibitors that are more effective against
AR than against aldehyde reductase.
Conclusions: The active site of AR adapts itself to bind tightly to different
inhibitors; this happens both upon binding to the inhibitor’s hydrophilic heads,
and at the hydrophobic and specificity pockets of AR, which can change their
shape through different conformational changes of the same residues. This
flexibility could explain the large variety of possible substrates of AR.
Introduction 
Although the physiological role of aldose reductase (AR;
EC1.1.1.21) in healthy individuals is still a matter of
debate, the enzyme is believed to be of primary impor-
tance in the development of severe degenerative compli-
cations of diabetes mellitus, through its ability to reduce
excess D-glucose into D-sorbitol in noninsulin-dependent
tissues [1]. AR has been shown to act on a wide range of
substrates in vitro, such as aldehydes, aldoses and corticos-
teroids, but it is most effective on steroid hormones [2], as
confirmed by a recent report [3]. This NADPH-depen-
dent enzyme reduces a carbonyl oxygen to a hydroxyl in
an ordered ‘bi-bi’ mechanism, in which NADPH is bound
first and NADP+ released last. Like all other NAD(P)-
dependent enzymatic reactions described to date, this
reduction is stereospecific with respect to the coenzyme.
Upon formation of the enzyme–coenzyme–substrate
ternary complex, a hydride is transferred from the C4
carbon atom of the nicotinamide ring (hydrogen 4-pro-R
of the A-face of the ring) of NADPH [4,5] to the carbonyl
carbon of the substrate while a proton is provided by the
enzyme to the carbonyl oxygen.
Several crystallographic analyses have been performed on
AR; these include the solution of the structure of the
apoenzyme from pig lens [6] and of the human [7,8] and
pig [9] holoenzymes. These structural studies have
revealed that AR folds as a (b/a)8 barrel, and have also
shown that its catalytic site lies at the bottom of a deep
hydrophobic cleft.
Inhibiting AR would provide a way of avoiding the com-
plications of diabetes, and identifying inhibitors is, there-
fore, an important pharmaceutical goal. Various structur-
ally diverse compounds have been observed to inhibit this
enzyme, and they can be divided into four main classes
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according to their structures. The first class comprises
flavonoids such as quercetin [10]. The second class are
spirohydantoins, the most well known of which are
sorbinil [11] and alconil [12]. The third class are substi-
tuted acetic acids: different subclasses of these are exem-
plified by 1,3-dioxo-1H-benz[de]isoquinolines, such as
alrestatin [13], which was the first aldose reductase
inhibitor found to be orally active, by naphtalene deriva-
tives such as tolrestat [14], which is intensively studied,
including in large scale trials [15], by 3,4-dihydro-4-oxo-
phtalazines such as ponalrestat [16] and zopolrestat [17],
and by rhodanines such as epalrestat [18]. The fourth class
of AR inhibitors includes phenylsulfonylnitromethane
derivatives such as ICI215918 [19] and ZD5522 [20].
In this context, the structures of the complexes of AR with
the potent inhibitor zopolrestat [21] and with citrate,
cacodylate and glucose 6-phosphate have been deter-
mined [22]. These analyses have shown that all these mol-
ecules bind in the AR active site, and that they recognize a
specific anionic site delineated by the C4N of the nicoti-
namide coenzyme, the Oh of Tyr48 and the Nε of His110.
The inhibitor zopolrestat binds in a ‘specificity’ pocket in
the active site, which is accessible after a conformational
change of the enzyme.
In this work, we report the solutions of the crystal struc-
tures of complexes of the pig AR holoenzyme with the
noncompetitive inhibitors tolrestat and sorbinil. The
present study shows that both of these inhibitors bind in
the active site; the contacts between the inhibitors and the
active-site residues are analyzed. A kinetic explanation for
the apparent contradiction between the active site binding
and non-competitiveness of AR inhibitors has been given
by Nakano and Petrash [23] for the case of zopolrestat. We
find that the inhibitors tolrestat and sorbinil recognize the
same anionic site as zopolrestat, and that tolrestat binds in
the same specificity pocket as zopolrestat. The orienta-
tions of the hydrophobic moieties of tolrestat and zopolre-
stat in this pocket are, however, quite different, and the
conformation of the specificity pocket varies according to
the inhibitor that is bound.
Results and discussion
The enzyme structure
The structure of the pig AR holoenzyme [9] has now been
obtained at 2.8 Å resolution from a tetragonal crystal form
with one monomer per asymmetric unit, and further
refined to 2.0Å resolution (see Materials and methods).
This structure, which is very similar to that of the human
holoenzyme, folds as a (b/a)8 barrel, with the coenzyme
binding on the top of the barrel (Fig. 1a) and the active
site at the bottom of a deep hydrophobic pocket. The very
high structural similarity of the pig and human enzymes
might possibly extend to the other ARs of known
sequence (bovine lens, rabbit kidney, rat lens and mouse
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Figure 1
Overall views of the holoenzyme form of pig lens AR. (a) Schematic
drawing obtained using the program SETOR [37], showing the TIM
barrel structure (green), the sorbinil molecule (brown ball-and-stick)
and the NADP+ (dark blue ball-and-stick) lying between strands S7
and S8, with loop L7 in light blue bent over it. (b) View of the surface
of the molecule generated using the program GRASP [38], with the
sorbinil molecule (ball-and-stick) bound in the active-site cleft. The
colors correspond to electrostatic potential surfaces (positive in blue;
negative in red) calculated using charge distributions on all protein
residues using the program XPLOR [32], and on NADP+, from
Pavelites et al. [39]. Note the positively charged bottom of the pocket,
below the sorbinil molecule.
kidney), as they each have more than 84% sequence
identity with the pig enzyme.
As NADP+ was present during crystallization, which was
done under mildly acidic conditions, it is likely that the
form of AR crystallized is the complex with NADP+.
Further evidence for this idea comes from the similarity of
the structure of the pig holoenzyme to that of the known
structure of the human holoenzyme, which is AR com-
plexed with NADP+, and from the fact that endogenously
bound NADP+ was found in the first tetragonal crystals
formed, even though no coenzyme was added during the
original purification and crystallization (data not shown).
Coenzyme binding 
Comparative analysis of the crystal structures of the apo-
enzyme [6] and the holoenzyme shows that the binding of
AR to NADPH, involving numerous interactions similar to
those reported for the human holoenzyme [7], requires
significant conformational changes in AR. The most
important conformational change  concerns loop 7, which
spreads over the coenzyme (Fig.1a); Trp20 and Lys21
within this loop each occupy two different positions in the
two forms of AR, corresponding to the opening and
closing of a latch formed by the bulky aromatic tryptophan
residue and a salt bridge between Lys21 and Asp216.
These conformational changes probably account for the
ordered bi-bi mechanism displayed by the enzyme and
also possibly for its low turnover. Indeed, it has been
shown that NADP+ release is the rate-limiting step of the
AR-catalyzed reduction of D-glyceraldehyde [24,25].
The active site
The nicotinamide ring of the coenzyme is largely buried
at the bottom of a deep cleft, which is approximately
4 ×15Å wide and 15Å deep (Fig. 1b), situated at the
C-terminal side of the cylindrical sheet above strands S1
and S2. The only accessible atoms of NADPH are C5, and
the hydride donor C4, thus defining the cleft as the only
possible active site. The residues lining the cleft can be
divided into two groups (Tables 1 and 2).
The first group comprises the, mainly hydrophilic,
residues Asp43, Tyr48, Lys77, His110, Ser159, Asn160,
Gln183 and Tyr209 (Table 1). Totally conserved among
ARs, these residues form a tight network of hydrogen
bonds linked to the nicotinamide coenzyme (Fig. 2a).
Ser159, Asn160 and Gln183, which are hydrogen-bonded
to the amide group of the nicotinamide, assure the
precise positioning of the nicotinamide ring for stereo-
selective transfer of the 4-pro-R hydrogen. This network
of hydrogen bonds involves well-ordered water mol-
ecules, marked in Figure 2a as Wat1, Wat2 and Wat3.
The water molecule Wat1 occupies the anionic site,
between Tyr48 and His110. Also noteworthy is the
stacking interaction with Tyr209 (Fig. 2a), which sug-
gests stabilization of the positively charged aromatic
system formed upon oxidation of NADPH to NADP+
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Table1
Principal interactions of the residues in the hydrophilic network around nicotinamide (Fig. 2a).
Residue Active-site contacts Sorbinil Sorbinil Tolrestat Tolrestat
H-bond VdW Other VdW H-bond VdW H-bond
Asp43 Gln183 Salt bridge – – – –
NADP+ Lys77
Tyr48 Lys77 6 2 4 1
Wat1
Lys77 Tyr48 His110 Salt bridge – – – –
Cys44 Asp43
Wat2
His110 Asn160 Trp79 6 1 6 2
Wat1 Lys77
Wat2 Trp111
Ser159 NADP+ – – – –
Asn160




Gln183 Asp43 – – – –
NADP+
Tyr209 Wat3 Charge-transfer – – – –
complex
NADP+
The type of interaction — hydrogen bond (H-bond), van der Waal (VdW), or other — is indicated, as well as the number of inhibitor–protein contacts.
(observed in the holoenzyme crystal form) by a charge-
transfer complex. 
The second group of residues lining the cleft (Table 2), all
of which lie above the coenzyme, includes those that form
the walls of the hydrophobic cleft — Trp20, Trp79,
Trp111, Phe122, Pro218, Trp219, Cys298, Leu300 and
Val47. Trp20, Phe122 and Trp219 fully face the active
site, and are thus expected to make the major contacts
with a potential substrate, as confirmed by the structure of
the complexes of AR with tolrestat and sorbinil described
below. The structure of the AR–zopolrestat complex also
shows the existence of a specificity pocket, the residues of
which are also in the second group of cleft-lining residues
and include Thr113, Phe115, Val130, Ser302 and Cys303.
Residues Trp111, Phe122 and Leu300 are shared by both
the active site and the specificity pockets. These pockets
are occupied by a network of water molecules, marked
Wat1 to Wat11 in Figure 2b.
Modeling calculations performed by De Winter and von
Itzstein [26] showed that the protein residues involved in
possible hydrogen-bonding interactions with a substrate at
the bottom of the AR active site are Tyr48, His110 and
Trp111. Following their work, we have performed a
theoretical calculation of possible binding sites using the
program FLEXX [27]. It showed that the spherical caps
corresponding to the positions of possible hydrogen-bond
acceptors of these three residues intersect (Fig. 2c),
joining in an extended surface centered on the anionic site
between His110 and Tyr48, where the intersection is
largest. This surface, with a neighboring volume allowing
for differences in hydrogen-bond length, can be con-
sidered to be the recognition region for hydrogen-bond
acceptors. 
Inhibitor binding
Complexes of the AR holoenzyme and the inhibitors tol-
restat and sorbinil were prepared by soaking the holoen-
zyme crystals in a solution of inhibitor (see Materials and
methods). Following the studies by Nakano and Petrash
[23], binding of both inhibitors to the NADP+ and
NADPH forms of the holoenzyme was confirmed by mass
spectroscopy (A van Dorsselaer, personal communication).
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Table 2
Residues at the hydrophobic sides of the active site (A) and the specificity pocket (S).
Residue Position Sorbinil Sorbinil Tolrestat Tolrestat Sequence
VdW H-bond VdW H-bond conservation
Trp20 A 28 1 13 1 Conserved in 
(N–F) (N–S) ARs and AR1s
Trp79 A 2 – 2 – Conserved in 
ARs and AR1s
Trp111 A+S 4 1 12 1 Conserved in 
ARs and AR1s
Phe122 A+S 4 – 6 – Conserved in 
ARs and AR1s
Pro218 A – – – – Conserved in ARs;
Ala in AR1s
Trp219 A 2 – 2 – Conserved in ARs
Cys298 A 1 – – – Conserved in ARs;
Ile in AR1s
Leu300 A+S 2 – 4 1 Conserved in ARs;
(O–F) Pro in AR1s
Val47 A 3 1 1 – Conserved in ARs;
(O–F) Ile in human AR1
and pig AR1
Thr113 S – – 1 – Conserved in ARs;
Tyr in AR1s
Phe115 S – – 3 – Conserved in ARs
and AR1s
Val130 S – – 2 – Conserved in ARs;
Ile in human AR1
and pig AR1
Ser302 S – – 4 1 Conserved in ARs;
(O–F) extra loop in AR1s
Cys303 S – – 2 3 Conserved in ARs;
(N–F, S–F, S–O) extra loop in AR1s
AR–inhibitor interactions — number of hydrogen bonds (H-bond) or van der Waals (VdW) contacts — and sequence conservation in mammalian
ARs and aldehyde reductases (AR1s) are shown.
These inhibitors have a polar ‘head’ and a hydrophobic
ring system (Fig. 3). We generated difference maps, and
these clearly showed that the inhibitors bind into the
active site, with the polar head near the coenzyme (Fig. 4).
Inhibitor models were positioned in these difference maps
and the complexes were refined (see Materials and
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Figure 2
Details of the active site of pig lens AR.
(a) The group 1 residues and NADP+ are
shown in ball-and-stick form; the network of
hydrogen bonds is shown in dotted lines. The
water molecule Wat1 occupies the anionic
center. Note the stacking of Tyr209 and the
nicotinamide ring; the arrangement of the
rings corresponds to the geometry of a
charge-transfer complex. (b) View
perpendicular to (a), showing the network of
water molecules Wat1–Wat11 occupying the
active-site cleft. (c) View of the bottom of the
active site, generated using the program
FLEXX [27], showing the possible sites for
binding hydrogen-bond acceptors (red caps)
and hydrogen-bond donors (yellow caps). The
protonation state of His110 at Nε2 is the one
proposed by De Winter and von Itzstein [26];
our current work with inhibitor docking tends
to confirm this choice (unpublished
observations). 
methods); in the case of sorbinil, there were no significant
changes in the enzyme structure, and in the case of tolre-
stat, there was a displacement of Leu300 and Phe122.
Tables 1 and 2 show the contacts of the inhibitors with the
enzyme, which can be classified into hydrophilic contacts
at the bottom of the site, hydrophobic contacts and water-
mediated contacts.
Hydrophilic contacts at the bottom of the site 
Sorbinil
In the case of sorbinil, there are two carboxyl oxygens, O2
and O3, with an NH group in the middle; the oxygens and
nitrogen make a tight hydrogen-bonding network with
Tyr48, His110 and Trp111 of AR (Fig. 5a), and are in
close contact with the bottom of the site: firstly, the O2
atom is between the OH group of Tyr48 (hydrogen bond),
the C4N of nicotinamide and the Cg of Trp20 (at dis-
tances of 2.7Å, 3.2Å and 3.1 Å, respectively); secondly, the
N2 atom occupies a middle site at 2.9Å from the Nε2 of
His110, 3.2Å from the OH group of Tyr48 and 3.5Å from
the C4N of nicotinamide; and thirdly, the O3 atom is at
3.0Å from the Nε2 of His110 (hydrogen bond) and 2.9 Å
from the Nε1 of Trp111 (hydrogen bond). The sorbinil
could also be in a second tautomeric state, in which the
hydrogen is on O2 or O3 and the N2 atom has a lone pair
of electrons; in this case, the N2 atom would make a
hydrogen bond to His110 andTyr48. 
These three atoms (O2, O3 and N2 of sorbinil) mark three
possible hydrophilic binding centers on AR: one between
Trp20 and Tyr48, the second between Tyr48 and His110
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Figure 3
Two dimensional chemical representation of (a) sorbinil and (b) tolrestat.
Figure 4
Difference maps showing (a) sorbinil and (b)
tolrestat in the active site of AR. The
difference maps Fo–Fc are calculated at 3 Å,
using the phases from the native enzyme. For
sorbinil, the density indicates clearly that the
S-enantiomer is bound, in agreement with the
inhibition studies in solution [1]. Note the
conformational change of the sidechain of
Leu300, necessary to accommodate the
tolrestat molecule. 
(corresponding to the anionic site) and the third between
His110 and Trp111 (Figs 5a and 6a). All three centers are
inside the recognition region defined theoretically using
the program FLEXX; centers 2 and 3, which can make
two hydrogen bonds, are in the region of the intersection
of the corresponding spherical caps (see Fig. 2c). A repre-
sentation of the protein surface with the electrostatic
potential shows that all three centers are on top of a posi-
tively charged region, which is quite extended and cen-
tered below the anionic site (Figs 1b and 7a).
Tolrestat
Tolrestat has a COOH hydrophilic head, similar to that
of many AR substrates. Given the pKa of tolrestat (4.5),
this head is probably bound by AR in the form (COO)–,
with the negative charge shared between atoms O2 and
O3. As in the case of sorbinil, these atoms are bound to
Tyr48, His110 and Trp111 through a tight hydrogen-
bond network, and are in close contact with the bottom
of the active site (Figs 5b and 6a): firstly, O2 is at a dis-
tance of 2.7 Å from the Oη of Tyr48 (hydrogen bond),
2.6 Å from the Nε2 of His110 (hydrogen bond) and 3.2 Å
from the C4N of nicotinamide; and secondly, O3 is at
2.8 Å from the Nε1 of Trp111 (hydrogen bond) and 3 Å
from the Nε2 of His110 (hydrogen bond). Note that the
hydrogen-bond donor character of the Oη of Tyr48 is
accentuated by the presence of Lys77; furthermore, the
C4N atom of nicotinamide is 3.3 Å from the C16 atom of
tolrestat. Referring to the hydrophilic binding centers of
AR defined by sorbinil, both centers 2 and 3 are occu-
pied by the negatively charged oxygens O2 and O3 of
tolrestat, respectively.
Analysis of the structures of AR complexes with zopol-
restat (Fig. 6a), cacodylate and glucose 6-phosphate show
that, in these structures, the hydrophilic binding centers 2
and 3 of AR are also occupied. In the case of the AR
complex with citrate, centers 1 and 2 are occupied by
negatively charged oxygens, and there is an extra inter-
action with Trp111. Our analysis of eight other inhibitor
complexes shows occupation of the same centers, with a
preference for center 2 (unpublished observations).
Therefore, all three centers can accommodate negative
charges depending on the structure of the inhibitor;
center 2, which corresponds to the anionic site, is clearly
the most occupied one.
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Figure 5
Hydrophilic binding site. (a) Binding of
sorbinil to the hydrophilic active site of AR.
Note the tight hydrogen-bond network
(dashed lines). Atoms O2, N2 and O3 mark
the three possible hydrophilic centers. (b)
Binding of tolrestat to the hydrophilic active
site. Note the tight hydrogen-bond network
(dashed lines).
Hydrophobic contacts and water-mediated interactions 
Sorbinil
The sorbinil molecule occupies the bottom of the active
site, between Trp20 on one side and Trp111–Phe122–
Leu300 on the other. The ring system is stacked against
Trp20, making 29 contacts (Fig. 6a). The binding of
sorbinil displaces the water network formed by Wat1 and
Wat4–Wat8 that occupied the active site. On the other
hand, two new water molecules, Wat12 and Wat13
(Fig. 5a) link the sorbinil molecule to the protein. 
Tolrestat
The chain between C13 and C16 of tolrestat emerges
from the anionic sites making mostly van der Waals con-
tacts with Trp20 of AR (Fig. 6a), with a possible hydrogen
bond between the S1 atom of the tolrestat molecule and
Ne1 of Trp20 (3.8Å). The hydrophobic ring system of tol-
restat gets trapped tightly in a pocket formed by Trp111,
Leu300 and Phe122, making 13 contacts with Trp111
(Fig. 6b). The opening of this pocket (the specificity
pocket; see below) requires a conformational change at the
level of the sidechains of Leu300 and Phe122. The O1
end of the tolrestat molecule is in contact with the C4
atom of Phe115 of AR, while the F atoms pack against
Ser302 and Cys303, with an OH–F bond with the OH of
Ser302 (Fig. 6b). The binding of tolrestat displaces the
water network formed by Wat1 and Wat4–Wat9 that occu-
pied the active site and the specificity pocket.
The hydrophobic pockets marked by these two inhibitors
are, therefore, the bottom of the active site (between
Trp20 and Trp111–Phe122) and the specificity pocket
(between Trp111, Leu300 and Phe122). These two
pockets have already been noted in the structure of the
AR–zopolrestat complex, where the first one traps the
phtalazinone ring and the second one traps the benzothia-
zole ring, making 65 contacts altogether. Note that the
mutation of Trp20 into alanine stops sorbinil inhibition,
has a large effect on tolrestat inhibition and has a less
marked effect on zopolrestat inhibition [28]. This is con-
sistent with the relative importance of the two hydropho-
bic pockets in binding the different inhibitors: sorbinil is
bound mostly to Trp20 (29 contacts) and does not open
the specificity pocket, whereas tolrestat makes an equal
number of contacts to Trp20 and Trp111 and zopolrestat
is bound mostly to Trp111. 
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Figure 6
Comparison of bound inhibitors. (a)
Superposition of the inhibitors sorbinil (green),
tolrestat (blue) and zopolrestat (red) with the
residues of the hydrophilic active site of AR
(orange). Note how all three inhibitors share
centers S2 and S3, and that sorbinil occupies
center S1. (b) Superposition of the
complexes of AR with sorbinil (green),
tolrestat (blue) and zopolrestat (red) with the
native protein (orange). Note the changes of
the sidechains of Leu300, Phe122 and
Ser302 for the tolrestat structure. For
zopolrestat, only the Ca atoms of the AR
residues are shown; note their displacement.
The specificity pocket
As noted above, the binding of both tolrestat and zopolre-
stat requires a conformational change in AR that opens the
specificity pocket, which is contiguous with the active-site
pocket. In the case of the native enzyme or the
AR–sorbinil complex, the specificity pocket is closed,
(Fig. 7b) and the residues Trp111, Phe122, and Leu300
form one hydrophobic wall of the active site pocket, with
Phe122 and Leu300 4Å away (Fig. 6b). In the case of the
AR–zopolrestat complex, the loops 121–135, containing
Phe122, and 299–302, containing Leu300, move in concert
[21], so that the Leu300–Phe122 contact is kept but they
shift away from Trp111, creating a space for the zopolrestat
molecule (Fig. 6b). In the case of the AR–tolrestat
complex, only the sidechains of Leu300 and Phe122 move
significantly and apart from each other (Fig. 6b), creating a
space for placing the tolrestat molecule at a position per-
pendicular to that occupied by zopolrestat in the
AR–zopolrestat complex (Figs 6b and 7a).
Therefore, even though the specificity pocket involves the
same residues in both cases, the way it opens to bind
zopolrestat and tolrestat is different, and leads to distinct
orientations of the bound inhibitors. Zopolrestat is stacked
parallel to Trp111, whereas tolrestat packs between
Phe122 and Leu300, perpendicular to Trp111; zopolrestat
goes more deeply into the pocket, with one F atom hydro-
gen-bonded to Thr113, whereas in tolrestat the F atom is
hydrogen-bonded to Ser302, much closer to the pocket
opening. In short, while they share the same pocket,
binding of tolrestat requires much fewer structural changes
to AR than binding of zopolrestat.
A role for the specificity pocket
It is interesting to note that while sorbinil inhibits both AR
and aldehyde reductase with similar IC50 values [29]
(5.4mM for aldehyde reductase and 2mM for AR), tolrestat
and zopolrestat inhibit AR more than than inhibit alde-
hyde reductase (the IC50 values are 0.72 and 27.0 mM for
aldehyde reductase and 0.01 and 0.06 mM for AR, respec-
tively) [29]. This strongly suggests that, whereas sorbinil
binds both enzymes in a similar way, tolrestat and zopolre-
stat bind them differently. We performed a sequence com-
parison of mammalian ARs and aldehyde reductases in
order to analyze the conservation of residues involved in
inhibitor binding (see Materials and methods). As shown
in Table 2, active site residues that are strongly involved
in sorbinil binding are conserved in both enzymes.
Whereas most of the specificity pocket residues involved
in tolrestat binding tend to be conserved in mammalian
ARs, however, they vary in aldehyde reductases. In partic-
ular, Leu300 is conserved in ARs but is replaced by
Pro301 in aldehyde reductase; Thr113 is conserved in AR,
but is replaced in aldehyde reductase by Tyr115; and
Ser302 is conserved in AR, but in aldehyde reductase
there is an extra loop, from Pro301 to Arg312, inserted at
this position. The insertion of this extra loop changes the
nature of the pocket and could explain the difference in
tolrestat binding. Furthermore, in the case of  zopolrestat,
the replacement of Thr113 of AR by Tyr115 in aldehyde
reductase takes up the space that the  inhibitor molecule
occupies in the zopolrestat–AR complex.
Ongoing crystallographic studies on inhibitors AL1576
(imirestat) and Amino SNM show that, like sorbinil, they
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Figure 7
Changes in the AR molecular surface corresponding to inhibitor
binding. (a) Superposition of tolrestat on a molecular surface of the
protein; note that the conformational changes have opened the
specificity pocket, which is occupied by the inhibitor. (b) Superposition
of sorbinil on a molecular surface of the AR protein, in the same
orientation as in (a); note that the inhibitor occupies the active-site
pocket. Figure was generated using the program GRASP [38].
bind the active site of AR without opening the specificity
pocket (our unpublished observations). Since AL1576 is
specific for aldehyde reductase [27], our observations
further confirm the role of the specificity pocket. 
Biological implications
Diabetes is a debilitating disease leading to severe com-
plications and a shortened life expectancy. In noninsulin-
dependent tissues, insulin therapy does not prevent the
occurrence of these complications, which include neuro-
pathy, retinopathy, nephropathy and cataracts. Under
conditions of diabetic hyperglycaemia, excess glucose is
metabolized by the polyol pathway, which comprises two
enzymes: aldose reductase (AR), which reduces excess
D-glucose into D-sorbitol, and sorbitol dehydrogenase,
which converts sorbitol to fructose. Diabetic complica-
tions have been linked to excessive accumulation of
sorbitol, leading to an interest in stopping the polyol
pathway through the inhibition of AR. This NADPH-
dependent enzyme reduces a carbonyl group to a hyd-
roxyl one in an ordered ‘bi-bi’ mechanism, in which
NADPH is bound first and NADP+ released last. The
catalytic site of AR is at the bottom of a deep hydro-
phobic cleft which recognizes a large variety of sub-
strates, ranging from glucose to steroid hormones. To
understand this promiscuous binding, the structures of
the complexes of AR with two inhibitors, sorbinil and
tolrestat, have been determined. This study has phar-
maceutical interest, as tolrestat and sorbinil have been
widely tested clinically with the aim of preventing
complications associated with diabetes.
Both inhibitors bind into the active site of AR, their
polar heads being recognized by an extended system of
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Table 3
Statistics of data collection and refinement for the solutions of the structures of the native AR enzyme and the complexes of AR
with the two inhibitors.
Object Native Sorbinil Tolrestat
Space group P43212 (96) P43212 (96) P43212 (96)
Unit cell: a, c (Å) 68.09, 153.35 67.92, 152.80 68.42, 153.56
Diffraction data:
resolution 2.0–15.0 2.3–15.0 2.3–15.0
No. reflections 24329 13052 15449
completeness (%) 97 79 92
completeness at the 93 45 66
highest resolution (%) (2.0–2.1) (2.3–2.4) (2.3–2.4)
Shell
Rsym (%)* 5.1 4.9 4.5
Rigid body refinement:
Rinit (3–8 Å)† 27.6 39.7 38.9
overall shift 0.14 Å, 0° 0.35 Å, 0.1° 0.46 Å, 0.1°
Rfinal (3–8 Å)† 26.3 24.0 25.4
Refinement:
resolution 2.0–6.0 2.3–6.0 2.3–6.0
N reflections (F > 2s) 23487 12147 14456
Rstart (Rfree)† 26.7 (33.9) 23.0 (31.8) 24.9 (32.5)
Rfin (Rfree)† 20.1 (28.5) 19.2 (26.3) 20.7 (29.0)
Final model:
protein residues 315 315 315
coenzyme 1 1 1
inhibitor – 1 1
water molecules 277 174 150
Geometrical statistics:
∆bond (Å) 0.012 0.011 0.011
∆angle (°) 2.88 2.78 2.80
∆impr (°)‡ 1.19 1.14 1.17
∆dihe (°)‡ 24.8 24.9 25.1
Ramachandran plot§:
favourable regions (%) 90.0 90.0 89.3
additional regions (%) 10.0 10.0 10.7
In general, R = S(F1–Fobs)/S(Fobs), in which Fobs = experimental
structure factor amplitude. *For Rsym, F1 = symmetry related
experimental structure factor amplitude. †For Rinit, Rfinal, Rstart and Rfin,
F1 = model structure factor amplitude, corresponding to the beginning
of the rigid body refinement, end of the rigid body refinement,
beginning of the atomic refinement and end of the atomic refinement,
respectively. ‡Ddihe = < a–ao >, in which a is the dihedral angle, and
Dimpr = < b–bo >, in which b is an angular value used by X-PLOR to
define chirality or planarity. §The Ramachandran plot was calculated
with the program PROCHECK [40]. 
three hydrophilic centers near the coenzyme. The
hydrophobic ring system of sorbinil binds to the native
active site, while that of tolrestat binds into a pocket
opened by conformational changes in the walls of the
active site cleft. These conformational changes are dif-
ferent from those previously observed for the inhibitor
zopolrestat, which binds the same pocket. Inhibitor
binding into this ‘specificity’ pocket is correlated with a
tighter binding to AR than to aldehyde reductase, a
closely related enzyme. 
The conservation of key residues in ARs from different
species and their differences from the equivalent residues
in aldehyde reductase suggest that the specificity pocket
binds substrates unique to AR. The different ways in
which the specificity pocket opens leads to tight packing
of different inhibitors by the same residues; this property
might prove to extend to different substrates. Therefore,
the study of these AR–inhibitor complexes and the con-
formational changes induced by the inhibitors explains
some of the remarkable adaptability of the active site of
AR, as well as its specificity for certain inhibitors.
Materials and methods
Purification and crystallization of the pig AR holoenzyme
Pig eyes collected from freshly slaughtered animals were immediately
frozen on dry ice. The lenses were extracted, frozen on dry ice and
stored at –20°C until used. The compounds D-xylose, dithioethreitol
(DTT) and MES were obtained from Sigma or Boehringer-Mannheim,
NADP and NADPH from Boehringer-Mannheim, xylitol from AR2ich
Chemicals, and polyethylene glycol (PEG) 3000 and 6000 and EDTA
from Fluka.
The purification [30] was performed at 4°C and all the buffers were
degassed with argon. Pig lenses (100 g) were homogenized in a
Waring blender for 2 min in 200 ml buffer A (50 mM phosphate buffer
pH 7.0, 1 mM EDTA, 5 mM DTT, 0.002% hibitane). The homogenate
was centrifuged at 10 000 rpm for 90 min. The supernatant was
brought to 30% (w/v) PEG 3000 by adding 1.0 vol of a 60% (w/v)
PEG 3000 solution in buffer A, and stirred for 1 h under argon. After
centrifugation as above, the supernatant was diluted with water
(600 ml) and loaded on a DEAE 50 Sephadex column (200 ml), equili-
brated with buffer B (20 mM phosphate buffer pH 7, 1 mM EDTA, 1 mM
DTT). The elution was performed first with buffer B (500 ml) and then
with a gradient of buffer B (600 ml) and of 0.5 M phosphate buffer
pH 7.0, 1 mM EDTA, 1 mM DTT (600 ml). The flow rate was 20 ml h–1
and fractions of 10 ml were collected. The fractions with the highest
activity were concentrated with an Amicon PM 10 membrane. The con-
centrated fractions were dialyzed against 25 mM MES buffer pH 6.2,
1 mM EDTA, 5 mM DTT (three times 1l), concentrated in Centricon
PM 10 microconcentrators (Amicon), and the activity of the purified
enzyme was tested and protein determination was performed.
The crystals of holoenzyme were grown using the hanging-drop method
by vapor diffusion with PEG6000. The drop concentration was
15mgml–1 AR, 2 equivalents of NADP+ in 75mM MES buffer pH6.2,
1mM EDTA, 1mM DTT, 2.5% PEG 6000 (w/v), and the well contained
the same buffer with 25% PEG 6000 added. Suitable crystals were
obtained within 10 days. The complexes of AR with the inhibitors were
obtained in the following way: the crystals were transferred to a capillary,
the mother liquor was removed and a solution containing the inhibitor
was added (120mM TES buffer pH6.2, 1mM EDTA, 1mM DTT, 30%
PEG 6000 (w/v), and either 10mM sorbinil or 62mM tolrestat).
Determination of the AR holoenzyme structure at 2.8Å
resolution
The structure of the porcine AR holoenzyme was obtained as follows:
tetragonal crystals of AR were obtained at 4°C in MES buffer (25 mM,
pH 6.2), using PEG 6000 (20%) as the precipitant. The space group
was P43212 with unit cell dimensions a = b = 68.5 Å, c = 153.9 Å, and
one monomer per asymmetric unit. Data were collected to 2.8 Å resolu-
tion from one crystal mounted on a high brilliance rotating anode, using
a Siemens area detector, and treated with the XDS package [31]. The
overall Rsym was 5.6% on intensities for 9093 independent reflections
above 3σ, obtained from 46 450 observations (overall completeness
above 3σ= 94%). 
A mercury derivative was prepared by soaking the crystal in ethyl-
mercury chloride (0.9 mM, 10 days). It revealed three mercury sites,
which were found to have the same relative positions and occupancies
as the sites of the mercury derivative obtained for the apoenzyme
(space group P1). This phenomenon was used to calculate the rota-
tions and translations that place the model of the apoenzyme in the
tetragonal cell of the holoenzyme crystals. A few cycles of rigid-body
refinement at very low resolution (∞–20 Å) were necessary to slightly
correct the position of the model (R factor of 35.5%). Unexpectedly
(since no NADPH had been added to the crystallization buffer), the
Fourier difference map computed after a few cycles of energy minimiza-
tion showed clear electron density for endogenously bound NADP+.
The complex including the coenzyme was then refined by energy mini-
mization and slow-cooling dynamics (X-PLOR [32]), with a final crystal-
lographic R factor of 21.3% for all the measured reflections in the
8.0–2.8 Å resolution range and of 20.5% for the reflections with ampli-
tudes F > 2σ (F) in the same resolution range (97.2% of the total
number). No water molecules were included.
Refinement of the AR holoenzyme structure at 2.0Å resolution
and structure determination of the enzyme–inhibitor complexes
Complexes of the holoenzyme with tolrestat or sorbinil were obtained
by soaking improved holoenzyme crystals in a solution containing
inhibitor. These inhibitor-soaked crystals diffracted at a synchrotron to a
resolution of 2 Å and were isomorphous to the improved native ones
(see Table 3 for statistics). Diffraction data for the native structure were
then measured again using a larger crystal and a synchrotron source.
This led to a clear improvement of the limits of the diffraction data, from
2.8 Å to 2.0 Å (see Table 3 for statistics). The previously determined
model was used as the starting point of a refinement, which included a
rigid-body refinement step, a slow-cooling step, a Powell minimization
and a temperature-factor refinement. Water molecules were placed in a
difference map. 
On the basis of this refined native structure, we performed a series of
steps for both AR–inhibitor complexes: first, placement and rigid-body
refinement of the native model in the complex unit cell at 3 Å resolution;
second, analysis of the difference density maps at 3 Å resolution; third,
manual model correction for tolrestat (following difference map); fourth,
refinement of the model without an inhibitor at the resolution of 2.3 Å;
fifth, insertion of the inhibitor model into the improved density map; and
sixth, refinement of the model of the complex including manual correc-
tions. At the step of rigid-body refinement and calculation of the first
maps, residues 116–133 and 213–223, which form flexible loops,
were removed from the starting model. Their position was observed in
the maps to be very close to those in the native model and therefore
they could be easily inserted back at the second step.
For both complexes, the density maps showed clearly the presence of
the inhibitor in the active center (Fig. 4). The quality of the density was
very high and the inhibitor models were built without any difficulty. The
programs O [33] and X-PLOR [32] were used for the model building
and refinement. Large differences between the protein models which
demanded a manual correction were observed for the two N-terminal
residues (different for all three structures) and for Leu300 in the tolre-
stat complex.
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The analysis of the weighted density maps, where the phase error esti-
mates from the refined models were calculated by RFLEXPL [34],
clearly showed the presence of a number of water molecules. The first
sets of water molecules (about 100) were placed automatically and
independently for both inhibitors using the program MAPMAN [35]. It is
interesting to note that about 90% of these water molecules were
placed in similar positions for tolrestat and sorbinil. These water mol-
ecule sets were edited, extended and refined together with the models
of the complexes.
Accession numbers
The coordinates of the sorbinil complex (accession number 1ah0), the
tolrestat complex (accession number 1ah3) and the native holoenzyme
(accession number 1ah4) have been deposited in the Protein Data Bank.
Sequence alignment
The known sequences of mammalian ARs (pig, bovine, rat, mouse,
rabbit and human) and aldehyde reductases (human, rat and pig) were
retrieved from the SwissProt Data Bank. The sequences were aligned
using the program PILEUP of the GCG package [36], with default
values for all the parameters.
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